The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome

References

• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:671–683.
   PubMed Web of Science ®Google Scholar
• Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989;320:559–565.
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93–99.
   PubMed Web of Science ®Google Scholar
• Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435–442.
   PubMed Web of Science ®Google Scholar
• Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110–3116.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801–810.
   PubMed Web of Science ®Google Scholar
• Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535–582.
   PubMed Web of Science ®Google Scholar
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160–2165.
   PubMed Web of Science ®Google Scholar
• Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453–2455.
   PubMed Web of Science ®Google Scholar
• Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, et al The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2–5.
   PubMed Web of Science ®Google Scholar
• Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The Relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:6061–6067.
   PubMed Web of Science ®Google Scholar
• Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592–5596.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. American association of clinical endocrinologists polycystic ovary syndrome writing committee. Endocr Pract 2005;11:126–134.
   Google Scholar
• Carmina E, Lobo RA. Polycystic Ovary Syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897–1899.
   PubMed Web of Science ®Google Scholar
• Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131–137.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520–525.
   PubMed Web of Science ®Google Scholar
• Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998;69:236–241.
   PubMed Web of Science ®Google Scholar
• Benson S, Janssen OE, Hahn S, Tan S, Dietz T, Mann K, Pleger K, Schedlowski M, Arck PC, Elsenbruch S. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 2008;22:177–184.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123–127.
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:863–861.
   Google Scholar
• Giallauria F, Palomba S, Manguso F, Vitelli A, Maresca L, Tafuri D, Lombardi G, Colao A, Vigorito C, Orio F. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;68:88–93.
   Google Scholar
• Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589–1595.
   PubMed Web of Science ®Google Scholar
• La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993;87:25–34.
   PubMed Web of Science ®Google Scholar
• Mackness MI, Harty D, Bhatnagar PH, Winocour S, Arrol M, Ishola M, Durrington PN. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193–199.
   PubMed Web of Science ®Google Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473–480.
   PubMed Web of Science ®Google Scholar
• La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001;29:566–569.
   PubMed Web of Science ®Google Scholar
• van Himbergen TM, van Tits LJ, Roest M, Stalenhoef AF. The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 2006;64:34–38.
   PubMed Web of Science ®Google Scholar
• Isik B, Ceylan A, Isik R. Oxidative stress in smokers and non-smokers. Inhal Toxicol 2007;19:767–769.
   PubMed Web of Science ®Google Scholar
• Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002;132:3012–3017.
   PubMed Web of Science ®Google Scholar
• Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003;52:1287–1294.
   PubMed Web of Science ®Google Scholar
• San Millán JL, Cortón M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metabol 2004;89:2640–2646.
   PubMed Web of Science ®Google Scholar
• McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671–673.
   PubMed Web of Science ®Google Scholar
• Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812–1818.
   PubMed Web of Science ®Google Scholar
• Dursun P, Demirtaş E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006;21:104–108.
   PubMed Web of Science ®Google Scholar
• Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007;52:879–883.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
   Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;42:678–687.
   Google Scholar
• Ducan MH, Singh BM, Wise PH, Carter G. Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995;346:120–121.
   Google Scholar
• Katz A, Nambi SS, Mather K. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–2410.
   PubMed Web of Science ®Google Scholar
• Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–1470.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J Clin Invest 1995;95:2409–2415.
   PubMed Web of Science ®Google Scholar
• Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A, Breteler MM, Witteman JC. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in non-diabetic elderly: the Rotterdam study. J Clin Endocrinol Metabol 2001;86:4398–4405.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003;11:987–996.
   PubMedGoogle Scholar
• Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665–668.
   PubMed Web of Science ®Google Scholar
• Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-a stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod 1999;61:993–998.
   PubMed Web of Science ®Google Scholar
• Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The 597 G-A and 174 G-C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002;87:1134–1141.
   PubMed Web of Science ®Google Scholar
• Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlösser HW, Brabant G, Schöfl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525–532.
   PubMed Web of Science ®Google Scholar
• Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90:6014–6021.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004;89:806–811.
   PubMed Web of Science ®Google Scholar
• Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 1994;330:460–465.
   PubMed Web of Science ®Google Scholar
• Sayin NC, Gucer F, Balkanli-Kaplan P, Yuce MA, Ciftci S, Kucuk M, Yardim T. Elevated serum TNF-alpha in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003;48:165–170.
   PubMed Web of Science ®Google Scholar
• Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP, Legro RS. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006;55:1076–1082.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, Xu M, Du PF, Li XY, Ning G. Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 2006;29:419–423.
   PubMed Web of Science ®Google Scholar
• Nasiek M, Kos-Kudła B, Ostrowska Z, Marek B, Kudła M, Siemińska L, Kajdaniuk D, Foltyn W, Zemczak A. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 2007;14:23–28.
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Alexandraki K, Piperi C, Protogerou A, Katsikis I, Greece Paterakis T, Lekakis J, Panidis D. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006;36:691–697.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426–1431.
   PubMed Web of Science ®Google Scholar
• Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23:505–510.
   PubMed Web of Science ®Google Scholar
• Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113:1203–1209.
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002;110:74–76.
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511–516.
   PubMed Web of Science ®Google Scholar
• Bickerton AS, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C, Cummings MH. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005;58:151–154.
   PubMed Web of Science ®Google Scholar
• Olszanecka-Glinianowicz M, Banaś M, Zahorska-Markiewicz B, Janowska J, Kocełak P, Madej P, Klimek K. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol 2007;133:97–202.
   Google Scholar
• Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007;92:4609–4614.
   PubMed Web of Science ®Google Scholar
• Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338–3342.
   PubMed Web of Science ®Google Scholar
• Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-a concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metabol 1999;84:272–278.
   PubMed Web of Science ®Google Scholar
• Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:336–340.
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T, Nerup J, Reimers JI, Pociot F, Andersen HU, Karlsen A, Bjerre U, Bergholdt R. Cytokines and the endocrine system I. The immunoendocrine network. Eur J Endocrinol 1995;133:660–671.
   Google Scholar
• Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R Pannitteri G. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002;32:9–15.
   PubMed Web of Science ®Google Scholar
• Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W. Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology 2002;98:116–122.
   Google Scholar